A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC

Inclusion criteria

• Signed the Informed Consent Form;
• Male or female ≥ 18 and≤75 years of age;
• Life expectancy ≥ 12 weeks;
• Eastern Cooperative Oncology Group Performance Status (ECOG PS) score is 0 or 1
• Have at least 1 lesion (not previously irradiated) with an accurately measured longest diameter ≥ 10 mm by computed tomography (CT) or magnetic resonance imaging (MRI) (intravenous contrast agent is preferred) at baseline (except lymph nodes which must have short axis ≥ 15 mm) according to RECIST V1.1 and lesions amenable to repeated accurate measurements.
• Histologically or cytologically confirmednon-small cell lung cancer

Exclusion criteria

• Previous exposure to immune-mediated therapy; previous use of antitumor vaccine;
• Received the last anti-tumor therapy within 4 weeks prior to the first dose of study drug;
• Received any investigational agent within 4 weeks prior to the first dose of study drug;
• Received systemic treatment with Chinese herbal medicine indicated for cancer or drugs used for immunoregulation (including thymosin, interferon, interleukin, except for local use for pleural effusion) within 2 weeks before the first dose;
• Are participating in another interventional clinical study, or observational (non-interventional) clinical study or in the follow-up phase of an interventional study;